Antiviral activity and safety of LB80380 in hepatitis B e antigen-positive chronic hepatitis B patients with lamivudine-resistant disease

Hepatology

Volumn 51, Issue 3, 2010, Pages 767-776

  Yuen, Man Fung ^a   Han, Kwang Hyub ^b   Um, Soon Ho ^c   Yoon, Seung Kew ^d   Kim, Hye Ryon ^e   Kim, John ^e   Kim, Chung Ryeol ^e   Lai, Ching Lung ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b Yonsei University College of Medicine   (South Korea)

^c Korea University College of Medicine   (South Korea)

^d The Catholic University of Korea   (South Korea)

^e LG Chemical Ltd   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 9 (1 PHOSPHONOMETHOXYCYCLOPROPYLMETHYL)PURINE BIS(PIVALOYLOXYMETHYL) ESTER; ADEFOVIR; ALBUMIN; BILIRUBIN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ABDOMINAL DISCOMFORT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ANTIVIRAL ACTIVITY; ARTICLE; BILIRUBIN BLOOD LEVEL; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FATIGUE; FEMALE; HEADACHE; HEPATITIS B; HUMAN; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MYALGIA; OPEN STUDY; PATIENT MONITORING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RHINORRHEA; SEROCONVERSION; SEROLOGY; SIDE EFFECT; UPPER ABDOMINAL PAIN; VIRUS LOAD;

ADULT; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS; YOUNG ADULT;

EID: 77950606642     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.23462     Document Type: Article

References (15)

1. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339:61-68.
2. Lai CL, Yuen MF. Chronic hepatitis B\new goals, new treatment. NEngl J Med 2008;359:2488-2491.
3. Lai CL, Yuen MF. The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points. Ann Intern Med 2007;147:58-61.
4. Yuen MF, Seto WK, Chow DH, Tsui K, Wong DK, Ngai VW, et al. Long-term lamivudine therapy reduces the riskof long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir Ther 2007;12:1295-1303.
5. Peters MG, Hann HW, Martin P, Heathcote EJ, Buggisch P, Rubin R, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004;126: 91-101.
6. Tenney DJ, Pokornowski KA, Rose RE, Baldick CJ, Eggers BJ, Fang J, et al. Entecavir at five years shows long-term maintenance of high genetic barrier to hepatitis B virus resistance. Hepatol Int 2008;2:A88-A89.
7. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008;359:2442-2455.
8. Trojan J, Stuermer M,TeuberG,Berger A, Faust D. Treatment of patients with lamivudine-resistant and adefovir dipivoxil-resistant chronic hepatitis B virus infection: is tenofovir the answer? Gut 2007;56:436-437.
9. Villet S, Ollivet A, Pichoud C, Barraud L, Villeneuve JP, Trépo C, et al. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J Hepatol 2007;46:531-538.
10. Fung J, Lai CL, Yuen MF. LB80380: a promising new drug for the treatment of chronic hepatitis B. Expert Opin Investig Drugs 2008;17:1581-1588.
11. Kim GW, Roh KY, Kim J. Evaluation of mitochondrial toxicities of new phosphonate derivatives. Intersci Conf Antimicrob Agents Chemother 2002;42:F1691.
12. Yuen MF, Kim J, Kim CR, Ngai V, Yuen JC, Min C, et al. A randomized placebo-controlled, dose-finding study of oral LB80380 in HBeAg-positive patients with chronic hepatitis B. Antivir Ther 2006; 11:977-983.
13. Min CH, Kim CR, Steffy K, Averett D, Locarnini S, Shaw T. The active metabolite of LB80380/ANA380, a novel nucleotide analog, exhibits activity in vitro against multiple clinically relevant hepatitis B virus mutants. J Hepatol 2007;46(Suppl 1):S159.
14. Sherman M, Yurdaydin C, Sollano J, Silva M, Liaw YF, Cianciara J, et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006;130:2039-2049. (Pubitemid 43816960)
15. van Bömmel F, Wünsche T, Mauss S, Reinke P, Bergk A, Schürmann D, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. HEPATOLOGY 2004;40: 1421-1425